EC
VNDA icon

EntryPoint Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

EntryPoint Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,520
Closed -$82.7K – 891
2025
Q2 		$82.7K Buy
+17,520
New +$76.6K 0.04% 574

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

EntryPoint Capital's VNDA Position: Q3 2025 in Review

EntryPoint Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 17,520 shares — an estimated $82.7K sold.

EntryPoint Capital first reported a position in VNDA in Q2 2025 and held it in 1 quarter. The position peaked at $82.7K in Q2 2025. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • EntryPoint Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • EntryPoint Capital sold 17,520 Vanda Pharmaceuticals shares in Q3 2025, an estimated $82.7K.
  • EntryPoint Capital first reported a position in Vanda Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • EntryPoint Capital's Vanda Pharmaceuticals position peaked at $82.7K in Q2 2025.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.